Ozempic Gastroparesis Attorney: Lawsuit Eligibility Overview

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Awareness to Targeted Exposure Concerns

For decades, the domain of general health and science information has served as a foundational resource for public awareness, offering broad guidance on wellness, disease prevention, and medical advancements. This legacy heritage established a baseline understanding of how lifestyle, environmental factors, and therapeutic interventions intersect with human health. Within this context, the public has been educated about the importance of monitoring medication side effects and recognizing when a treatment may pose unforeseen risks. As the landscape of pharmaceutical science evolves, a specific area of concern has emerged that requires a focused pivot from general health education to a more targeted occupational exposure inquiry. The widespread use of glucagon-like peptide-1 receptor agonists, such as Ozempic, has introduced a new dimension of patient safety considerations. Specifically, reports of gastroparesis—a condition characterized by delayed gastric emptying—have prompted legal and medical scrutiny. This transition from broad health literacy to a precise exposure concern is necessary to address the potential liability and eligibility for legal recourse among individuals who have used Ozempic and subsequently developed gastroparesis. The shift underscores the need for specialized evaluation of pharmaceutical exposure and its documented consequences.

Bridging to Ozempic and Gastroparesis

Building on the legacy of general health education, we now turn to a specific pharmaceutical exposure that has raised significant safety questions. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes and, in some formulations, for weight loss. Among its known side effects, gastrointestinal adverse reactions are prominent. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (placebo 0%, 0.5 mg 2.7%, 1 mg 1.1%), flatulence (placebo 0.8%, 0.5 mg 0.4%, 1 mg 1.5%), gastroesophageal reflux disease (placebo 0%, 0.5 mg 1.9%, 1 mg 1.5%), and gastritis (placebo 0.8%, 0.5 mg 0.8%, 1 mg 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Understanding Gastroparesis and Its Link to Ozempic

Gastroparesis is a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. The clinical presentation of gastroparesis overlaps significantly with the gastrointestinal adverse effects reported with Ozempic, including nausea, vomiting, dyspepsia, and gastroesophageal reflux disease. Mechanistically, GLP-1 receptor agonists like semaglutide slow gastric emptying as part of their pharmacodynamic action. This delay in gastric emptying is a known effect that can contribute to symptoms of gastroparesis. While the prescribing information for Ozempic does not explicitly list gastroparesis as a specific adverse reaction, the reported gastrointestinal adverse reactions—particularly nausea, vomiting, dyspepsia, and gastroesophageal reflux disease—are consistent with the clinical features of gastroparesis. The frequency of these events, especially during dose escalation, suggests a potential mechanistic pathway linking Ozempic to gastroparesis-like symptoms.

Legal Considerations and Eligibility for Lawsuits

The adequacy of warnings regarding Ozempic and gastroparesis is a critical consideration for affected patients. The prescribing information for Ozempic includes warnings about serious hypersensitivity reactions, such as anaphylaxis and angioedema, which have been reported in patients treated with Ozempic (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, there is no specific warning about gastroparesis. The gastrointestinal adverse reactions are listed under adverse reactions, but the label does not explicitly caution about the potential for gastroparesis or delayed gastric emptying as a distinct clinical entity. This lack of specific warning may be relevant for patients who develop severe or persistent gastrointestinal symptoms that meet the diagnostic criteria for gastroparesis. For patients who have experienced gastroparesis after using Ozempic, attorney-related considerations include evaluating whether the manufacturer provided adequate warnings about the risk of gastroparesis. The timeline between exposure to Ozempic and documented harm is important. Gastrointestinal adverse reactions, including those consistent with gastroparesis, often occur during dose escalation, as noted in clinical trials (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Patients who develop symptoms shortly after starting Ozempic or after a dose increase may have a stronger temporal association. Documenting the onset of symptoms, the duration of Ozempic use, and any diagnostic evaluations for gastroparesis (such as gastric emptying studies) is essential for establishing a link.

Summary of Evidence and Next Steps

In summary, the evidence indicates that Ozempic is associated with a range of gastrointestinal adverse reactions that overlap with the clinical presentation of gastroparesis. The prescribing information does not include a specific warning about gastroparesis, which may be a point of contention in legal claims. Patients who have experienced severe or persistent gastrointestinal symptoms while using Ozempic should consult with a healthcare provider for proper diagnosis and consider legal counsel to evaluate potential claims related to inadequate warnings. References: - https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is gastroparesis and how is it related to Ozempic?

Gastroparesis is a condition characterized by delayed gastric emptying without mechanical obstruction, causing symptoms like nausea, vomiting, and bloating. Ozempic (semaglutide) slows gastric emptying as part of its mechanism, and its gastrointestinal side effects overlap with gastroparesis symptoms. Clinical trials show higher rates of nausea, vomiting, and dyspepsia in Ozempic users compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does the Ozempic label warn about gastroparesis?

No, the prescribing information for Ozempic does not include a specific warning about gastroparesis. While gastrointestinal adverse reactions are listed, there is no explicit caution about the potential for gastroparesis or delayed gastric emptying as a distinct clinical entity (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

What are the eligibility criteria for an Ozempic gastroparesis lawsuit?

Eligibility typically requires documented use of Ozempic, a confirmed diagnosis of gastroparesis (e.g., via gastric emptying study), and a temporal association between Ozempic use and symptom onset. The lack of adequate warnings about gastroparesis may strengthen a claim. Consulting an attorney is recommended to evaluate individual circumstances.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Ozempic Prescribing Information

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.